TGTX · Tg Therapeutics, Inc. · Documents
Market Cap
$8.25B
Shares
153.07M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-05 | 2026-06-30 | |
| 8-K | 2026-08-03 | — | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| Investor Event Transcript | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-06-03 | — | |
| 8-K | 2026-05-27 | — | |
| 8-K | 2026-05-06 | — | |
| 10-Q | 2026-05-06 | 2026-03-31 | |
| DEF 14A | 2026-04-30 | 2026-06-11 | |
| 8-K | 2026-03-20 | 2026-03-18 | |
| 10-K | 2026-02-27 | 2025-12-31 | |
| 8-K | 2026-02-26 | — | |
| 8-K | 2026-01-13 | — | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-03 | — | |
| 10-Q | 2025-08-08 | 2025-06-30 | |
| 8-K | 2025-08-04 | — | |
| 8-K | 2025-06-13 | 2025-06-12 | |
| 10-Q | 2025-05-09 | 2025-03-31 | |
| 8-K | 2025-05-05 | — | |
| DEF 14A | 2025-04-30 | 2025-06-12 | |
| 10-K | 2025-03-03 | 2024-12-31 | |
| 8-K | 2025-03-03 | — | |
| 8-K | 2025-01-14 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-11-04 | — | |
| 10-Q | 2024-08-09 | 2024-06-30 | |
| 10-K/A | 2024-08-09 | 2023-12-31 | |
| 8-K | 2024-08-06 | 2024-08-02 | |
| 8-K | 2024-06-17 | 2024-06-14 | |
| 10-Q | 2024-05-06 | 2024-03-31 | |
| 8-K | 2024-05-01 | — | |
| DEF 14A | 2024-04-29 | 2024-06-14 | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2024-02-28 | — | |
| 8-K | 2024-01-10 | 2024-01-07 | |
| 10-Q | 2023-11-06 | 2023-09-30 | |
| 8-K | 2023-11-01 | — | |
| 10-Q | 2023-08-04 | 2023-06-30 | |
| 8-K | 2023-08-01 | 2023-07-28 | |
| 8-K | 2023-06-15 | 2023-06-14 | |
| 10-Q | 2023-05-08 | 2023-03-31 | |
| DEF 14A | 2023-05-01 | 0001-01-01 | |
| 8-K | 2023-05-01 | — | |
| 10-K | 2023-03-01 | 2022-12-31 | |
| 8-K | 2023-02-28 | — | |
| 8-K | 2022-12-28 | — | |
| 8-K | 2022-11-10 | — | |
| 10-Q | 2022-11-09 | 2022-09-30 |
Showing 1–50 of 94 filings
Key facts
CIK
1001316
CUSIP
88322Q108
13F (30d)
101 filings
100 filers
Visit website
Investor relations